Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies for fibrotic diseases. Their mission is to build the leading fibrosis company by combining expertise in fibrosis-biology, chemistry, and technology to develop best-in-class, tissue-specific inhibitors of fibrotic diseases. They aim to transform the lives of patients suffering from debilitating and deadly fibrotic diseases.

Pliant Therapeutics

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Pliant Therapeutics is a late-stage clinical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases

We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates aimed at halting or even reversing fibrotic diseases and address the unmet needs of many patients.

Pliant’s co-founders include world-renowned researchers from the University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

Cormorant Asset Management

Cowen Healthcare Investments

Eventide

Novartis Institutes for Biomedical Research

Redmile Group

Agent Capital

Logos Capital

S-Cubed Capital

Schroder Adveq

Menlo Ventures

Join members of #TeamPliant this week at the 2023 PFF Summit hosted by the Pulmonary Fibrosis Foundation. We are proud to be a Gold Sponsor of this event. Visit our booth and learn about BEACON-IPF, our clinical trial enrolling patients in IPF.  

#pffsummit

Today we presented our third quarter 2023 financials and provided a company update. Read about our 2023 accomplishments and 2024 milestones. https://lnkd.in/gAvSRpdb

Today we announced that we will participate in upcoming investor conferences hosted by Stifel Financial Corp., Evercore and Piper Sandler. See details on the fireside chats: https://lnkd.in/gqT439Hy

Teams presented three posters highlighting PLN-101095, a novel inhibitor of integrins αvβ8, and αvβ1, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. More on these presentations: https://lnkd.in/gXinxcdC #SITC2023 #SITC23

Looking forward to sharing our work with the oncology community this week at the Society for Immunotherapy of Cancer (SITC)'s Annual Meeting. View the abstracts: https://lnkd.in/eaPTMwXS
#SITC2023 #SITC23

Join a leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Learn more about Pliant’s culture, our active DEI initiatives, benefits and current openings: https://lnkd.in/gjPhTFf

#TeamPliant

Sunday is Global PSC Awareness Day. Our Plianteers will be joining the patient, caregiver and medical communities to acknowledge primary sclerosing cholangitis, a rare, progressive liver disease of unknown origin that occurs in all ages, genders, and races for which there are no current treatments. Learn more about this important day from PSC PARTNERS SEEKING A CURE: https://lnkd.in/gGVw3FSC   #PSCaware

Excited that our INTEGRIS-PSC Phase 2a data was selected for an oral late-breaker presentation at American Association for the Study of Liver Diseases (AASLD)’s The Liver Meeting® 2023. https://lnkd.in/gjBwk4fC

Pleased to welcome S. Mishima Gerhart as our Chief Regulatory Officer. Mishima is a recognized biopharmaceutical leader who brings global regulatory expertise and experience leading cross-functional teams across multiple therapeutic areas. Learn more about Mishima: https://lnkd.in/gGJYr_ve

We welcomed the Pulmonary Fibrosis Foundation and their Annual PFF Walk to the Bay Area where members of #TeamPliant came out in force to support a very worthy cause. This event highlights our shared commitment to raising awareness and funds to support the important patient and educational initiatives of the PFF. This year our Plianteers raised more than $20,000! Join us for a walk or come by our booth in Washington DC this weekend or in Dallas on October 21st! https://lnkd.in/gupva3M6

COM:PLIANTRX

Pliant Therapeutics

Last Close

12.85

22/11 21:00

Market Cap

669.01M

Beta: -

Volume Today

586.02K

Avg: -

name

homepage url

country

linkedin url

employee count

sector

industry

revenue

Description

investor of

Metrics